China cracks down on foreign business

As China moves from manufacturer to consumer, foreign firms are coming into direct competition with domestic players. Plenty of evidence suggests they're getting treated unfairly.

The view from the trenches at that moment among the foreign business community is that doing business in China has become more difficult, not less. The most recent European Union Chamber of Commerce in China ‘Business confidence survey’ (June 2013) showed 53 per cent of respondents citing market access barriers as being a significant challenge to their future business in China, while 47 per cent cited discretionary enforcement of regulations. In the same survey, 30 per cent of respondents said that the regulatory environment has increasingly discriminated against foreign investors or is generally much less fair now than it was two years ago.

 The ‘FDI Regulatory Restrictiveness Index’ compiled by the Organisation for Economic Co-operation and Development (OECD) identifies China as having the most ‘closed’ economy among all OECD and G20 nations, having regard to foreign equity limitations, screening or approval mechanisms, restrictions on the employment of foreigners and operational restrictions.

Sectors that remain restricted or wholly closed to foreign investment include key areas where Australian businesses possess particular know-how and competitive advantage: energy and natural resources, and agriculture. These also happen to be the sectors that are most attractive to Chinese investors seeking to invest in Australia.

While this is patently unfair, the gap also presents an opportunity for Australian policy-makers to push their Chinese counterparts for a policy of ‘reciprocity’ to prevail – to highlight that Australia welcomes Chinese investment, but expects the same treatment for its companies in China as it affords Chinese investors in Australia. This reciprocity should extend to market access, approval processes and other restrictions.

One of the biggest challenges facing foreign investors has been fairness in treatment and consistency in application of regulations and policies. This has been manifested in three key areas;

Food and health safety and standards.

Food safety is an increasingly sensitive political issue in China as numerous food scandals – from melamine-tainted milk powder to diseased pork, from cadmium rice to exploding watermelons – have drawn the ire of the populace, putting pressure on the authorities to investigate and punish offenders and reassure its people that they can eat safely.

However, foreign companies appear to be frequent and public targets of these investigations, as local officials eager to show that they are serious about tackling food safety issues see foreign operators as easier targets, as they are not entrenched local interests, and lack political protection. Such food safety crackdowns are often accompanied by adverse publicity campaigns in state-run media.

Recent targets have included:

  • Wal-Mart, which was subject to a number of charges, including mislabelling regular pork as more expensive organic pork, a scandal which led to the temporary closure of thirteen stores and the arrest of two employees, and selling products with hazardous levels of chemicals. Wal-Mart has since agreed to invest RMB100 million to strengthen food safety management at its stores in China.
  • KFC, one of the most long-standing and successful Western businesses in China, which faced an online outcry and falling sales after Chinese food regulators announced they had found excessive levels of antibiotics and hormones in chickens from some KFC suppliers, and more recently a CCTV media reported that its ice cubes contained excessive levels of bacteria.

Anti-trust and consumer investigations

Since China introduced its first comprehensive trade practices law in the form of the Anti-Monopoly Law of 2008, much of the focus internationally has been on the role of the Ministry of Commerce (‘Mofcom’) in overseeing merger control under the new law. Mofcom has made rulings on a number of overseas merger and acquisition transactions, as it seeks to become a globally influential antitrust regulator alongside the US Department of Justice and the European Commission.

However, it is the lesser remarked upon role of the National Development and Reform Commission (‘NDRC’) as the frontline regulator on pricing practices and anti-competitive behaviour that is having an increasing impact on foreign business on the ground in China. Its actions in preventing monopolies and unfair pricing practices also serve a political goal: pushing down prices for consumers is good public relations for the Chinese government, and at the same time supports Beijing’s efforts to boost the consumer-led economy.

Again, foreign companies have been apparently disproportionately subject to the NDRC scrutiny, in a number of recent cases:

  • In 2011, global consumer products giant Unilever was fined RMB2 million for announcing to the media that intended to raise prices. Prices were never actually raised, but Unilever was fined in any event for allegedly creating a consumer panic through its public statements.
  • A group of the five largest global infant formula manufacturers – including Nestlé and Danone among other prominent global players – agreed to reduce the prices of their infant formula products in China after the NDRC announced it was investigating the companies for alleged price fixing in China. The NDRC subsequently levied significant fines on a number of the companies.
  • The latest NDRC investigation has apparently been into foreign pharmaceutical pricing, although that has led to a broader corruption investigation, discussed below.

Bribery and corruption

Corruption is endemic in China, affecting all levels of government and business. Foreign companies also find themselves the target of corruption investigations, although again the timing and motivation for such investigations raise some questions.

In the most notable case for Australia, several Rio Tinto executives were jailed for accepting bribes and stealing commercial secrets. While not questioning the conclusions of the Chinese judicial process that found the Rio employees guilty, it is notable that the investigation came shortly after the collapse of Chinese state-owned mining giant Chinalco’s attempted investment in Rio Tinto and during a fraught annual benchmark iron ore price negotiation process.

Most recently, British pharmaceuticals giant GlaxoSmithKline has been charged with a scheme of bribery involving payments to officials and doctors. In the context of a chronically underfunded health system, rampant counterfeiting of drugs and poorly paid doctors who seek to supplement their salaries – whether with kickbacks from pharmaceutical firms or bribes from patients’ families to ensure priority treatment – there is clearly much that needs to be fixed in China’s health system. It is curious that a large foreign drug company should be the starting point. Notably, following the charges being laid, GlaxoSmithKline announced price cuts at the same time as confirming that some of its executives appeared to have breached Chinese law.

A way forward

None of the above is intended to excuse foreign companies for their misbehaviour in China. All companies must fully comply with the local law in all countries where they do business, and those that do not should be penalised in accordance with the law. However, concerns remain about the consistency and fairness with which such laws are applied to foreign businesses in China. There are also concerns that the public relations exercises in state-controlled media that generally accompany regulatory investigations appear to be part of a strategy to discredit or constrain foreign businesses in their attempts to compete in the domestic consumer market.

Australian policy-makers should press their Chinese counterparts to ensure that:

laws and regulations are clearly drafted and publicly disseminated, and do not contain vague provisions that can be subject to discretionary interpretation by regulatory authorities;

foreign and domestic companies are treated fairly and consistently when it comes to the application of laws and regulations; and,

investigations are conducted transparently, sound evidence is provided to support allegations of misconduct and state-owned media are not favoured in dissemination of information on regulatory actions.

At the same time, foreign businesses in China need to understand that public relations and active image management is now just as important in China as it is in any other market. There once may have been a perception that China was ‘just’ a developing market, where investors could ignore public relations and take a lax approach to regulatory compliance. This is clearly no longer the case.

Greater fairness and equal treatment is needed in both directions: from foreign companies in operating their businesses in China, and from the Chinese government in regulating foreign business. This would lead to benefits for all involved. Australian governments and businesses should seek to be leaders in this respect, and place themselves at the forefront of a new era of engagement between China and the world.

Antony Dapiran is a partner of the international law firm Davis Polk & Wardwell, based in the firm’s Hong Kong office, where he advises on capital markets transactions and Chinese inbound and outbound mergers and acquisitions.

This article originally was published in the Australia-China Agenda, a publication of the Australian Centre on China and the World of ANU. It is has been edited for length.

No carousel of other videos after the video ends.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles